Showing 2001-2010 of 4063 results for "".
- ProQR Does Not Meet Primary or Secondary Endpoints in Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-Mediated LCA10https://modernod.com/news/proqr-does-not-meet-primary-or-secondary-endpoints-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10/2480633/
- Aldeyra Therapeutics to Modify Phase 3 TRANQUILITY -2 Trial in Dry Eye Disease After Missing Primary Endpointhttps://modernod.com/news/aldeyra-therapeutics-to-modify-phase-3-tranquility-trial-in-dry-eye-disease-after-missing-primary-endpoint/2480528/Aldeyra Therapeutics announced topline results from the Phase 3 TRANQUILITY trial of it investigational dry eye drug reproxalap. The primary endpoint of ocular redness was not met in TRANQUILITY, according to a company news release. However, statistical significance (P=0.0001) was
- ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patients-dosed-in-phase-23-pivotal-trials-of-qr-421a-for-ush2a-mediated-retinitis-pigmentosa/2480522/
- Oxurion Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-announces-first-patient-dosed-in-its-phase-2-study-evaluating-thr-687-for-the-treatment-of-dme/2480349/Oxurion announced that the first patient h
- Gyroscope Therapeutics Presents Positive Interim Phase 1/2 Data for Investigational Gene Therapyhttps://modernod.com/news/gyroscope-therapeutics-announces-presentation-of-positive-interim-phase-12-data-for-investigational-gene-therapy-gt005-at-retina-society-annual-scientific-meeting/2480312/Gyroscope Therapeutics announced positive interim data from the
- Oxurion Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-positive-results-from-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme/2480311/
- Sight Sciences Announces Publication of 2-Year Outcomes of Standalone Use of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-announces-publication-of-two-year-outcomes-of-standalone-use-of-the-omni-surgical-system-in-mild-to-moderate-open-angle-glaucoma/2479466/Sight Sciences announced publication in
- Ocuphire Announces Publication Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Diseasehttps://modernod.com/news/ocuphire-announces-publication-featuring-its-oral-ref-1-inhibitor-apx3330-in-phase-2-trial-for-the-treatment-of-retinal-disease/2479396/Ocuphire Pharma announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled “APE1/Ref-1 as a Novel Target for Retinal Disease.” The Journal of Cellula
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- NIH-Sponsored Trial Finds Eylea Reduced Vision-Threatening Complications by 68% After 2 Years in DR Patientshttps://modernod.com/news/nih-sponsored-trial-finds-eylea-reduced-vision-threatening-complications-by-68-after-2-years-in-diabetic-retinopathy-patients/2479034/Regeneron Pharmaceuticals announced that JAMA Ophthalmology has